Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Janux Therapeutics, Inc.NASDAQ: JANX
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin at -652.6%
Net margin was -652.6% in Q1 FY2026. On a trailing-twelve-month basis it was -529.7%, up 303.0 pp year over year. Over 3 fiscal years it narrowed by 404.0 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 11 analysts of -343.2% for the fiscal year ending Dec 2026, up from -1136.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -652.6%-247.2 pp QoQ
- Last fiscal yearDec 2025
- -1136.3%-484.6 pp YoY
- LTMMar 2026
- -529.7%+303.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -484.6 pp | +793.1 pp | +1277.7 pp |
| 3 years | -404.0 pp | -1960.1 pp | -1556.1 pp |
| 5 years | +984.2 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1136.3%
- Year-over-year change
- -484.6pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1136.3% | -484.6pp |
| FY2024 | 2024-12-31 | -651.6% | +69.6pp |
| FY2023 | 2023-12-31 | -721.2% | +11.0pp |
| FY2022 | 2022-12-31 | -732.2% | +166.1pp |
| FY2021 | 2021-12-31 | -898.3% | — |
Net Margin vs competitors
How JANX compares with its peers on the latest reported figures
- JANX's LTM Mar 2026 net margin of -529.7% is the 5th highest of the 8 companies compared; the peer median is -166.4%.
- Its year-over-year change of +303.0 pp is the highest of 8, against a peer median of -8.2 pp.
- Over three fiscal years its change of -404.0 pp compares with a peer median of +9.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | -0.0% | +26.4 pp | +352.6 pp | |
| LTM Mar 2026 | -44.8% | -8.2 pp | +29.9 pp | |
| LTM Mar 2026 | -154.2% | +214.9 pp | -10.6 pp | |
| LTM Mar 2026 | -166.4% | -194.6 pp | +164.0 pp | |
| LTM Mar 2026 | -529.7% | +303.0 pp | -404.0 pp | |
| LTM Mar 2026 | -574.9% | -559.9 pp | -428.7 pp | |
| FY2025 | -3060.0% | +180.4 pp | — | |
| LTM Sep 2026 | -275986.6% | -267350.8 pp | -12487.7 pp | |
| FY2025 | — | — | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding JANX) | -166.4% | -8.2 pp | +9.7 pp | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.64M | 8.61M | 8.08M | 10.59M | 10M |
| Cost of Revenue | 26.24M | 841K | 1.96M | 2.06M | 2.03M |
| Gross Profit | (22.6M) | 7.77M | 6.13M | 8.53M | 7.97M |
| Gross Margin | -621.4% | 90.2% | 75.8% | 80.5% | 79.7% |
| Research & Development | 26.24M | 53.44M | 54.92M | 68.39M | 125.9M |
| Selling, General & Admin | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M |
| Operating Expenses | 10.33M | 74.86M | 79.11M | 107.38M | 165.64M |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| EBITDA | (32.56M) | (62.22M) | (56.34M) | (66.93M) | (111.6M) |
| EBITDA Margin | -895.2% | -722.5% | -697.0% | -632.2% | -1116.0% |
| Operating Income | (32.93M) | (67.09M) | (72.98M) | (98.85M) | (157.67M) |
| Operating Margin | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Interest Income | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Income Before Tax | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Pre-Tax Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Net Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| EPS (Basic) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| EPS (Diluted) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| Weighted Avg Shares | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
| Weighted Avg Shares (Diluted) | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.